HCV Protease Inhibitors, Hepatitis B/Hepatitis C agents
No data available for drug.
Actions and Spectrum:
simeprevir is a direct-acting antiviral (DAA) medication used to treat chronic hepatitis C (HCV) infection. It works by inhibiting the protease enzyme of the hepatitis C virus, which is essential for viral replication. Doing so can prevent the virus from multiplying and spreading in the body.
simeprevir is a specifically targeted antiviral therapy (STAT), and it is used in combination with other antiviral agents, such as peginterferon and ribavirin, or other DAAs like sofosbuvir, to increase its effectiveness. This combination therapy can improve the cure rates for hepatitis C, even in patients who have previously failed other treatments
simeprevir has a broad spectrum of activity against HCV genotypes 1a and 1b, the most common HCV genotypes in North America, Europe, and Japan. It has limited or no activity against other HCV genotypes, such as 2, 3, 4, 5, or 6. Therefore, it is primarily used to treat HCV genotype one infection.
